Morgan Jessica E, Cleminson Jemma, Atkin Karl, Stewart Lesley A, Phillips Robert S
Centre for Reviews and Dissemination, University of York, Heslington, York, YO10 5DD, UK.
Department of Paediatric Haematology and Oncology, Leeds Teaching Hospitals NHS Trust, Great George Street, Leeds, LS1 3EX, UK.
Support Care Cancer. 2016 Jun;24(6):2651-60. doi: 10.1007/s00520-016-3074-9. Epub 2016 Jan 13.
Reduced intensity therapy for children with low-risk febrile neutropenia may provide benefits to both patients and the health service. We have explored the safety of these regimens and the effect of timing of discharge.
Multiple electronic databases, conference abstracts and reference lists were searched. Randomised controlled trials (RCT) and prospective observational cohorts examining the location of therapy and/or the route of administration of antibiotics in people younger than 18 years who developed low-risk febrile neutropenia following treatment for cancer were included. Meta-analysis using a random effects model was conducted. I (2) assessed statistical heterogeneity not due to chance.
PROSPERO (CRD42014005817).
Thirty-seven studies involving 3205 episodes of febrile neutropenia were included; 13 RCTs and 24 prospective observational cohorts. Four safety events (two deaths, two intensive care admissions) occurred. In the RCTs, the odds ratio for treatment failure (persistence, worsening or recurrence of fever/infecting organisms, antibiotic modification, new infections, re-admission, admission to critical care or death) with outpatient treatment was 0.98 (95% confidence interval (95%CI) 0.44-2.19, I (2) = 0 %) and with oral treatment was 1.05 (95%CI 0.74-1.48, I (2) = 0 %). The estimated risk of failure using outpatient therapy from all prospective data pooled was 11.2 % (95%CI 9.7-12.8 %, I (2) = 77.2 %) and using oral antibiotics was 10.5 % (95%CI 8.9-12.3 %, I (2) = 78.3 %). The risk of failure was higher when reduced intensity therapies were used immediately after assessment, with lower rates when these were introduced after 48 hours.
Reduced intensity therapy for specified groups is safe with low rates of treatment failure. Services should consider how these can be acceptably implemented.
对低风险发热性中性粒细胞减少症患儿采用降低强度的治疗方法可能对患者和医疗服务都有益。我们探讨了这些治疗方案的安全性以及出院时间的影响。
检索了多个电子数据库、会议摘要和参考文献列表。纳入了针对癌症治疗后发生低风险发热性中性粒细胞减少症的18岁以下人群的治疗地点和/或抗生素给药途径的随机对照试验(RCT)和前瞻性观察队列。采用随机效应模型进行荟萃分析。I²评估非偶然因素导致的统计异质性。
PROSPERO(CRD42014005817)。
纳入了37项研究,涉及3205例发热性中性粒细胞减少症病例;13项RCT和24个前瞻性观察队列。发生了4起安全事件(2例死亡,2例入住重症监护病房)。在RCT中,门诊治疗的治疗失败(发热/感染病原体持续、恶化或复发、抗生素调整、新感染、再次入院、入住重症监护病房或死亡)比值比为0.98(95%置信区间(95%CI)0.44 - 2.19,I² = 0%),口服治疗的比值比为1.05(95%CI 0.74 - 1.48,I² = 0%)。汇总所有前瞻性数据得出的门诊治疗失败估计风险为11.2%(95%CI 9.7 - 12.8%,I² = 77.2%),口服抗生素治疗的失败风险为10.5%(95%CI 8.9 - 12.3%,I² = 78.3%)。评估后立即采用降低强度治疗时失败风险较高,48小时后采用则失败率较低。
针对特定群体的降低强度治疗是安全的,治疗失败率较低。医疗服务机构应考虑如何以可接受的方式实施这些治疗。